J. Mendell

发表

The Effect of Rifampin on the Pharmacokinetics of Edoxaban in Healthy Adults

J. Mendell, Shuquan Chen, Ling He, 2015, Clinical Drug Investigation.

Unusual features of the T-system of the pectoralis muscle of the chicken.

J. Mendell, 1971, Journal of ultrastructure research.

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

M. Wolzt, S. Kapiotis, K. Ogata, 2011, Thrombosis and Haemostasis.

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

S. Connolly, J. Weitz, H. Kastrissios, 2010, Thrombosis and Haemostasis.

Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans

H. Masumoto, M. Bathala, J. Mendell, 2012, Drug Metabolism and Disposition.

Edoxaban administration following enoxaparin: A pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects

F. Lee, H. Zahir, J. Mendell, 2012, Thrombosis and Haemostasis.

Ex vivo reversal of the anticoagulant effects of edoxaban.

M. Samama, J. Mendell, A. Halim, 2014, Thrombosis research.

Population Pharmacokinetic Analysis of Quizartinib in Healthy Volunteers and Patients With Relapsed/Refractory Acute Myeloid Leukemia

A. Krämer, N. Russell, G. Martinelli, 2020, Journal of clinical pharmacology.

Safety and Pharmacokinetics of DS‐1040 Drug‐Drug Interactions With Aspirin, Clopidogrel, and Enoxaparin

C. Rambaran, F. Pizzagalli, F. Kobayashi, 2020, Journal of clinical pharmacology.

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

E. Antman, R. Giugliano, S. Zhou, 2012, Thrombosis and Haemostasis.

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

J. Mendell, S. Kunitada, Masaya Tachibana, 2011, Journal of clinical pharmacology.

Acrylamide and 2,5-hexanedione neuropathies: abnormal bidirectional transport rate in distal axons

Z. Sahenk, J. Mendell, 1981, Brain Research.

Modification by L-dopa of a case of progressive supranuclear palsy. With evidence of defective cerebral dopamine metabolism.

W. Engel, T. Chase, J. Mendell, 1970, Lancet.

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.

M. Samama, J. Mendell, L. Le Flem, 2012, Thrombosis research.

A Thorough Electrocardiogram Study of Edoxaban, a Novel Factor Xa Inhibitor

J. Morganroth, J. Mendell, A. Draves, 2011, Journal of clinical pharmacology.

Abuse potential of mirogabalin in recreational polydrug users

E. Sellers, H. Zahir, J. Mendell, 2019, Therapeutic advances in drug safety.

Patritumab with Cetuximab plus Platinum-Containing Therapy in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: An Open-Label, Phase Ib Study

K. Harrington, R. Beckman, M. Forster, 2018, Clinical Cancer Research.

Effect of Food on the Pharmacokinetics of Quizartinib

J. Mendell, M. Kankam, G. Gammon, 2020, Clinical pharmacology in drug development.

A drug–drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics

N. Cook, J. Mendell, Jianke Li, 2019, Cancer Chemotherapy and Pharmacology.

Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.

H. Kastrissios, S. Rohatagi, J. Mendell, 2012, Thrombosis and haemostasis.

A thorough QTc study demonstrates that olmesartan medoxomil does not prolong the QTc interval

J. Mendell, James Lee, N. Matsushima, 2015, Journal of clinical pharmacology.

Linear mixed‐effects model of QTc prolongation for olmesartan medoxomil

J. Mendell, James Lee, Saeheum Song, 2015, Journal of clinical pharmacology.

Tolerability, pharmacokinetics, and pharmacodynamics of mirogabalin in healthy subjects: Results from phase 1 studies

H. Zahir, J. Mendell, Ling He, 2018, Pharmacology research & perspectives.

Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer

Daniel J. Freeman, Z. Tsuchihashi, J. von Pawel, 2015, EBioMedicine.

Drug-Drug Interaction Studies of Cardiovascular Drugs Involving P-Glycoprotein, an Efflux Transporter, on the Pharmacokinetics of Edoxaban, an Oral Factor Xa Inhibitor

F. Lee, H. Zahir, J. Mendell, 2013, American Journal of Cardiovascular Drugs.

Edoxaban drug–drug interactions with ketoconazole, erythromycin, and cyclosporine

D. Parasrampuria, K. Truitt, H. Zahir, 2016, British journal of clinical pharmacology.

Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects

F. Lee, J. Mendell, Toshiyuki Sato, 2013, Clinical pharmacology in drug development.

The P-glycoprotein transport system and cardiovascular drugs.

R. Giugliano, Robert P Giugliano, J. Mendell, 2013, Journal of the American College of Cardiology.

An open‐label, phase 1 study to evaluate the effects of hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics

J. Mendell, Shuquan Chen, L. Johnson, 2015, Journal of clinical pharmacology.

Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans

Takako Shimizu, M. Yamada, H. Takakusa, 2018, Drug Metabolism and Disposition.

Pharmacokinetics of the Direct Factor Xa Inhibitor Edoxaban and Digoxin Administered Alone and in Combination

J. Mendell, R. Noveck, M. Shi, 2012, Journal of cardiovascular pharmacology.

Pharmacokinetics of the direct factor Xa inhibitor edoxaban and digoxin administered alone and in combination.

J. Mendell, R. Noveck, M. Shi, 2012 .

The Effects of the Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor

M. Samama, F. Lee, J. Mendell, 2013, Journal of cardiovascular pharmacology.

Drivers of Sexual Health Knowledge for Two-Spirit, Gay, Bi and/or Indigenous Men Who Have Sex with Men (gbMSM)

R. Hogg, Y. Keynan, Carl Marshall, 2021 .

Phase 2 HERALD study of patritumab (P) with erlotinib (E) in advanced NSCLC subjects (SBJs)

C. Schumann, R. Beckman, J. Tseng, 2015 .

Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors

J. Mendell, Shuquan Chen, N. Matsushima, 2016, Cancer Chemotherapy and Pharmacology.

Phase 1 Evaluation of [64Cu]DOTA-Patritumab to Assess Dosimetry, Apparent Receptor Occupancy, and Safety in Subjects with Advanced Solid Tumors

M. Welch, R. Laforest, B. Siegel, 2016, Molecular Imaging and Biology.

H reflex suppression by thalamic stimulation and drug administration.

K. Clark, J. Mendell, J. Stern, 1968, Journal of neurosurgery.

Thromboembolism and brain tumors.

J. Mendell, R. Brisman, 1973, Journal of neurosurgery.

Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Mirogabalin When Coadministered With Lorazepam, Zolpidem, Tramadol, or Ethanol: Results From Drug‐Drug Interaction Studies in Healthy Subjects

H. Zahir, J. Mendell, Ling He, 2018, Clinical pharmacology in drug development.

A randomized trial of the safety, pharmacokinetics and pharmacodynamics of edoxaban, an oral factor Xa inhibitor, following a switch from warfarin.

J. Mendell, R. Noveck, M. Shi, 2013, British journal of clinical pharmacology.

Low Concentrations of rhFVIIa or FEIBA Significantly and Rapidly Reverse the Anticoagulant Effects of Supratherapeutic Edoxaban

E. Stein, J. Mendell, A. Halim, 2011 .